Lower Gastrointestinal Conditions: Inflammatory Bowel Disease

Area of Science:

• Gastroenterology
• Immunology

Background:

• Inflammatory bowel disease (IBD) encompasses Crohn disease and ulcerative colitis (UC), arising from aberrant immune responses to gut microbes in susceptible individuals.
• Crohn disease affects the entire GI tract wall, while UC is limited to the colon's mucosal layer.

Purpose of the Study:

• To outline current management strategies for IBD.
• To highlight the roles of various therapeutic agents and the importance of ongoing patient monitoring.

Main Methods:

• Review of established and emerging treatments for IBD.
• Discussion of the specific applications and limitations of medications like steroids, methotrexate, 5-aminosalicylates, and biologics.
• Emphasis on the need for comprehensive health maintenance and surveillance in IBD patients.

Main Results:

• Steroids are effective for acute flares but limited by side effects.
• Methotrexate aids Crohn disease induction/maintenance (off-label).
• 5-Aminosalicylates are beneficial for UC; surgery is curative for UC but a last resort for Crohn disease.
• Biologic agents offer new therapeutic avenues.

Conclusions:

• IBD management requires a multi-faceted approach tailored to disease type and severity.
• Short-term steroid use is preferred due to adverse effects.
• Ongoing monitoring for IBD complications, including nutritional deficiencies, infections, and cancer, is essential for patient well-being.